Related by context. All words. (Click for frequent words.) 73 evaluable subjects 73 HBeAg seroconversion 72 complete cytogenetic response 71 HBeAg 71 CCyR 71 PSA nadir 71 mg/m2 dose 71 % CI #.#-#.# [003] 71 sUA 70 SVR# 70 mcg BID 70 posttreatment 70 HBeAg negative patients 70 achieved ACR# 70 genotypic resistance 70 pCR 70 biochemical relapse 70 REYATAZ r arm 70 mcg albinterferon alfa 2b 69 endoscopic remission 69 relapsed MM 69 complete cytogenetic 69 liver histology 69 certolizumab 69 underwent surgical resection 69 undetectable HCV RNA 69 PASI scores 69 remission CR 69 sustained virological response 69 CR nPR 68 Kaplan Meier analysis 68 postintervention 68 specific antigen PSA 68 HIV RNA 68 patients evaluable 68 underwent resection 68 ACR# responses 68 PEG IFN 68 dosing cohort 68 lamivudine refractory patients 68 ACR# response 68 tipranavir r 68 log# reduction 68 mg kg dose 68 timepoint 68 mucosal healing 68 seroconverted 68 CRp 68 lumbar spine BMD 67 dose cohort 67 definite stent thrombosis 67 evaluable 67 locoregional recurrence 67 histologically confirmed 67 detectable HCV RNA 67 HGPIN 67 lopinavir r arm 67 achieved CCyR 67 NNRTI resistance 67 posttransplant 67 virologic response 67 CANCIDAS 67 sustained virologic response 67 experienced virologic failure 67 CIN2 + 67 mg TID 67 randomized multicenter trial 67 virological response 67 elevated ALT 67 LEXIVA r 67 HBV DNA levels 67 HBV DNA 67 binary restenosis 67 MCyR 67 CIMZIA ™ 67 placebo dexamethasone 67 pT2 67 response CCyR 67 virologic failure 67 undetectable viral load 67 HBeAg positive patients 67 mg QD 67 pT3 67 HSCT 67 ARB telmisartan 67 receiving VICTRELIS 67 biochemical recurrence 67 haematologic 67 alanine aminotransferase ALT 66 #mg BID [001] 66 CLL SLL 66 partial remissions 66 ALT flares 66 oxycodone CR 66 achieved PASI 66 serum HBV DNA 66 bladder carcinoma 66 HBsAg 66 postoperative chemotherapy 66 #Gy 66 CR CRu 66 Primary endpoints 66 μmol L 66 caspofungin 66 pmol L 66 NSABP B 66 nondiabetic patients 66 mL/min/#.# m 2 66 cytogenetic response 66 HCV RESPOND 2 66 anti HBs 66 virologic response EVR 66 preoperative PSA 66 prospectively defined 66 rFSH 66 ALT normalization 66 DAS# remission 66 virologic breakthrough 66 DAS# CRP 66 dosing cohorts 66 8mg/kg 66 chlorambucil 66 abacavir lamivudine 66 Pharmacokinetic parameters 66 Doxil ® 66 undetectable hepatitis C 66 XIENCE V PROMUS Stent 66 angiographic outcomes 66 undetectable viral 66 -#.# log# 66 autologous SCT 66 euthyroid 66 #mg dose [002] 66 ACR Pedi 66 #.#ng/ml 66 aspartate aminotransferase AST 66 mg ustekinumab 66 ertapenem 66 Index CDAI 66 BARACLUDE ® 65 KRAS mutations occur 65 lanthanum carbonate 65 HIV uninfected 65 ug dose 65 #mg/day [001] 65 seronegative 65 mRCC 65 advanced adenomas 65 neoadjuvant chemotherapy 65 prior chemotherapy regimens 65 MADRS score 65 stage IIIb IV 65 colorectal liver metastases 65 retrospective cohort 65 SCIg 65 RECIST Response Evaluation Criteria 65 CIMZIA TM certolizumab pegol 65 Psoriasis Area 65 preoperative chemotherapy 65 cells mcL 65 Response Evaluation Criteria 65 advanced adenoma 65 histologically proven 65 elevated LDH 65 null responder 65 efavirenz EFV 65 methotrexate monotherapy 65 nicardipine 65 GOUT 65 PREZISTA r arm 65 antiretroviral naïve 65 prospectively enrolled 65 umol L 65 resected pancreatic cancer 65 piperacillin tazobactam 65 mcg doses 65 abacavir Ziagen 65 lopinavir r 65 FOLFOX6 65 Flu Cy 65 RECIST criteria 65 clinically meaningful improvement 65 primary patency 65 recurrent glioblastoma multiforme 65 TPV r 65 visceral metastases 65 seroprotection 65 mg BID dose 65 NMIBC 65 4mg/kg 65 R0 resection 65 adjuvant tamoxifen 65 serum HCV RNA 65 lymphocyte count 65 adenoma recurrence 65 underwent liver transplantation 65 melphalan prednisone 65 fluvastatin 65 heavily pretreated patients 65 SUVmax 65 ribavirin RBV 65 thyroglobulin 65 HBeAg positive 65 CC genotype 65 adefovir treated 65 antibody titer 65 HbA 1c levels 65 virological suppression 65 invasive carcinomas 64 lymphocytosis 64 Solid Tumors criteria 64 plasma pharmacokinetics 64 plus methotrexate 64 chemoradiation therapy 64 cEVR 64 MoxDuo TM IR 64 Crohn Disease Activity 64 clodronate 64 baseline HbA1c 64 ribavirin therapy 64 MBq 64 CsA 64 statistical significance p 64 serum prostate 64 pharmacodynamic PD 64 HBeAg negative 64 comparator arm 64 anagrelide 64 Partial Responses 64 morphometric vertebral fractures 64 IOP lowering 64 cinacalcet 64 nonmetastatic 64 serum testosterone 64 % Confidence Interval 64 hemodialysis patients 64 plus dexamethasone 64 tipranavir ritonavir 64 AZT zidovudine Retrovir 64 hepatectomy 64 statistically significant p 64 radical nephrectomy 64 rapid virologic response 64 IU ml 64 glycated hemoglobin levels 64 mesalamine granules 64 unfractionated heparin UFH 64 debulking surgery 64 CIMZIA TM 64 atazanavir ritonavir 64 total thyroidectomy 64 Free Survival PFS 64 Elitek 64 paclitaxel eluting stents 64 oral allopurinol 64 hypogonadal men 64 nadroparin 64 HIV HCV coinfected 64 Pharmacokinetics PK 64 daily subcutaneous injections 64 adjuvant cisplatin 64 #mg BID [003] 64 plasma uric acid 64 IFN α 64 Median PFS 64 micafungin 64 pegylated liposomal doxorubicin 64 TEAEs 64 anthracycline taxane 64 IPSS 64 QTcF 64 tPSA 64 noninferiority 64 Ishak fibrosis score 64 posaconazole 64 antiretroviral naive 64 timepoints 64 TURBT 64 F FDG PET 64 HER2 expression 64 adalimumab 64 pretransplant 64 cytologically confirmed 64 underwent CABG 64 cTnI 64 graft occlusion 64 corticosteroid dose 64 dacarbazine DTIC 64 CIN3 64 octreotide LAR 64 mcg QD 64 univariate analysis 64 β blockers 64 FOLFOX4 64 peginterferon alfa 2a #KD 64 mycophenolate mofetil 64 HLA A2 64 virologic suppression 64 viral kinetics 64 completely resected 63 mITT population 63 lactate dehydrogenase LDH 63 papillary renal cell carcinoma 63 serum urate 63 transaminase elevations 63 K#N 63 seropositivity 63 R# #mg BID 63 hemoglobin Hb 63 BENICAR HCT 63 intact parathyroid hormone 63 highly emetogenic 63 flutamide 63 HCV RNA 63 serum ALT 63 fosamprenavir 63 NIHSS 63 mg qd 63 HBeAg + 63 pharmacokinetic PK profile 63 ejection fractions 63 mutated K ras 63 dose melphalan 63 paclitaxel cisplatin 63 hematologic toxicity 63 amoxicillin clavulanate 63 desvenlafaxine succinate 63 achieved statistical significance 63 baseline LDH 63 serum phosphate 63 diameter stenosis 63 ritonavir boosted 63 mg BID 63 insulin detemir 63 null responder HCV 63 hematological parameters 63 VELCADE melphalan 63 doxorubicin docetaxel 63 achieved sustained virologic 63 prospectively stratified 63 evaluable patients 63 serum concentrations 63 achieved sustained virological 63 epoetin alpha 63 tolterodine ER 63 p = .# [002] 63 Target Lesion Revascularization TLR 63 chemoradiotherapy 63 systemic ALCL 63 adefovir 63 APTIVUS r 63 TLUS 63 goserelin 63 Pred Forte 63 neoadjuvant 63 mg p = 63 bovine thrombin 63 CDAI 63 NHANES III 63 T2 lesion volume 63 Solid Tumors RECIST 63 low dose Iluvien 63 locoregional 63 P = .# 63 pegylated interferon alpha 63 ng dL 63 concurrent chemoradiation 63 confirmed CCyR 63 paricalcitol 63 baseline Hb 63 tapentadol ER 63 squamous intraepithelial lesions 63 oral diclofenac 63 nadolol 63 urothelial carcinoma 63 galiximab 63 mL/min/#.# m2 63 EDSS scores 63 PSADT 63 GnRH agonist 63 sirolimus eluting stents 63 prespecified 63 DLTs 63 SGPT 63 efficacy endpoint 63 chest radiographs 63 nucleoside naive patients 63 protease inhibitor PI 63 urinary N telopeptide 63 q#h 63 oblimersen 63 transrectal ultrasound guided 63 multivariable analysis 63 KRAS status 63 resected tumors 63 5-FU/LV 63 Engerix B 63 CTAP# Capsules 63 recurrent GBM 63 concomitant antibiotics 63 treatment naïve genotype 63 TMC# r 63 irbesartan 63 dosage regimens 63 salmeterol fluticasone 63 immunostaining 63 Operative mortality 63 Pegasys plus Copegus 63 Retreatment 63 IELT 63 thrombocytopenic 63 administered subcutaneously 63 mCRC patients 63 adjunctive placebo 63 serum cortisol 63 LPV r 63 statistically significant p = 63 EBRT 63 metastatic CRC 63 aged ≥ 63 Virologic 63 external beam radiotherapy 63 secondary efficacy endpoints 63 ACR# ACR# 63 invasive aspergillosis 63 Secondary endpoints included 63 apolipoprotein B 63 microalbumin test 63 MGd 63 Hycamtin ® 63 hepatocellular carcinomas 63 operable breast cancer 63 ritonavir boosted lopinavir 63 T1c 63 PREZISTA r 63 #.#mg/dL 63 receiving highly emetogenic 63 mg RDEA# 63 azacytidine 63 â ‰ ¥ 63 HCV antibody 63 metastatic malignant 63 VP# [004] 63 radiotherapy RT 63 mCi kg 63 YERVOY 63 ACTEMRA TM 63 undergone radical prostatectomy 63 histological subtype 63 UGT#A# * 63 squamous histology 63 iPTH 63 XIENCE V demonstrated 63 ug kg 63 Renal Cell Carcinoma RCC 63 atorvastatin #mg 62 bronchoalveolar lavage 62 virologic failures 62 clinicopathological features 62 rFVIIa 62 -#.# ± [002] 62 heavily pretreated 62 briakinumab 62 extracapsular extension 62 chronic HBV 62 virological failure 62 hsCRP levels 62 EURIDIS 62 intravesical 62 VFEND 62 FOLPI 62 hip BMD 62 liver transplant recipients 62 median PFS 62 infliximab monotherapy 62 response pCR 62 μg kg 62 elevated troponin 62 interferon alfa 2b 62 HCV SPRINT 62 lymphadenectomy 62 cervical intraepithelial neoplasia 62 castrate resistant 62 interquartile range 62 scintigraphic 62 lymphovascular invasion 62 lymphopenia 62 Thal Dex 62 μg L 62 #mg q8h 62 seropositive patients 62 Histologic 62 median CD4 62 S. aureus isolates 62 MAGE A3 ASCI 62 stage IIIB 62 HIV seronegative 62 remission induction 62 antibody titers 62 n = 62 renal tumors 62 dacarbazine chemotherapy 62 Secondary endpoints 62 liver biopsies 62 moderately emetogenic 62 radical retropubic prostatectomy 62 seroconversion 62 AUA Symptom Score 62 #mg QD [001] 62 -#.# log# copies mL 62 achieved mucosal healing 62 μg mL 62 Pegylated Interferon 62 microg 62 Preoperatively 62 gastric adenocarcinoma 62 % CI #.#-#.# [007] 62 Bezielle 62 iodixanol 62 uM 62 receiving ISENTRESS 62 virologic responses 62 microgram kg 62 microbiologically evaluable 62 mg q#h 62 Peginterferon 62 severe neutropenia 62 Subgroup analysis 62 EDSS score 62 radiochemotherapy 62 nephrectomy 62 doxorubicin cyclophosphamide 62 Viral load 62 dalteparin 62 gemcitabine carboplatin 62 SLNB 62 alicaforsen enema 62 eculizumab therapy 62 prospectively evaluated 62 RRMS patients 62 hemoglobin A1c HbA1c 62 IV NSCLC 62 cells uL 62 GSK# [001] 62 titrated glipizide 62 mcg dose 62 Histological 62 perioperative mortality 62 breast carcinoma 62 OGTT 62 intravesical therapy 62 ascending dose 62 renal cell carcinomas 62 eosinophilic asthma 62 plasma HCV RNA 62 abnormal cytology 62 multivariate analyzes 62 somatostatin analog 62 chemoembolization 62 #mg QD [002] 62 HOMA IR 62 5-fluorouracil/leucovorin 62 rizatriptan 62 dexamethasone Decadron 62 hemoglobin A1c levels 62 tolvaptan 62 trastuzumab Herceptin ® 62 intravenous bolus 62 patients undergoing CABG 62 complete remissions 62 mcg mL 62 antiandrogen 62 MIC# [001] 62 eosinophil count 62 ORENCIA ® 62 ENDEAVOR II 62 non splenectomized 62 #mg ATC 62 q#d 62 T1a 62 HbA1C 62 NSTE ACS 62 postmenopausal osteoporotic women 62 bendamustine 62 HER2 positive metastatic breast 62 metastatic malignant melanoma 62 ovarian carcinoma 62 ALT elevations 62 standard chemotherapy regimen 62 Platinol ® 62 hepatic metastases 62 macrolide antibiotic 62 receiving INTRON 62 solifenacin 62 adjuvant radiotherapy 62 biliary tract cancer 62 dose cohorts 62 ALND 62 PANSS scores 62 TAXUS Express Stent 62 histologic subtype 62 Peg IFN 62 HCV replicon 62 log# copies mL 62 Angiographic 62 mIU mL 62 median survivals 62 Lucentis monotherapy 62 Liver biopsies 62 radical prostatectomy RP 62 FluCAM arm 62 baseline PASI 62 serum aminotransferase levels 62 unresectable HCC 62 advanced neoplasia 62 budesonide pMDI 62 pancreatic resection 62 fructosamine 62 oral rivaroxaban 62 mEq L 62 Viread Emtriva 62 HDRS 62 FDG-PET/CT 62 cytogenetic responses 62 carboplatin paclitaxel 62 coinfected 62 metastatic RCC 62 histologically 62 Scale EDSS score 62 undetectable virus HCV 62 cytoreduction 62 ceftazidime 62 noninferior 62 GLIADEL R Wafer 62 localized renal 62 alfa 2a 62 CHOP chemotherapy 62 histologic 62 mCi 62 acromegalic patients 62 graft dysfunction 62 Decitabine 62 Scale EDSS 62 hA# 61 Kaplan Meier 61 PREZISTA ritonavir 61 tumor histology 61 5 Fluorouracil 61 beta blocker therapy 61 seminal vesicle invasion 61 mg kg cohorts 61 CrCl 61 prespecified secondary 61 biopsy Gleason 61 pamidronate 61 alteplase 61 dose atorvastatin 61 postdose 61 CLARITY study 61 mcg kg 61 copies mL 61 multicenter randomized controlled 61 carotid endarterectomy CEA 61 NLX P# 61 preintervention 61 #mg/m# [001] 61 OPCAB 61 Partial Response 61 methacholine challenge 61 maternal serum 61 KRAS mutations 61 HCV infected 61 intradermal injections 61 baseline FEV 61 p = NS 61 cystectomy 61 vitreous haze 61 NATRECOR ® 61 ABSORB trial 61 DAS# scores 61 buprenorphine implants 61 NAbs 61 underwent radical cystectomy 61 GAMMAGARD 61 dapagliflozin plus 61 active comparator 61 #μg [002] 61 hepatorenal syndrome 61 μg dose 61 BENICAR 61 proctitis 61 peripheral blood mononuclear 61 MMSE score 61 imatinib therapy 61 undetectable viral loads 61 mitomycin 61 peg interferon 61 resectable 61 anthracycline containing 61 weekly intravenous infusions 61 cardiovascular calcification 61 serum PSA 61 genotype 1a 61 ß blockers 61 estimated GFR 61 μg liter 61 urodynamic 61 everolimus eluting stents 61 ‰ ¥ 61 K#R [002] 61 periprocedural 61 serum urate levels 61 ErbB2 positive 61 ULORIC 61 histologic subtypes 61 Pegylated Liposomal Doxorubicin 61 sirolimus stent 61 rosuvastatin #mg 61 FIRMAGON 61 prostate carcinoma 61 hemodynamically significant 61 PegIFN RBV 61 undergone splenectomy 61 Folfox 61 prucalopride 61 adjuvant radiation 61 viremia 61 idraparinux 61 nodular partial response 61 cytogenic 61 NRTI resistance 61 variant allele 61 pegylated interferon alfa 61 salmeterol fluticasone propionate 61 TDF FTC 61 pharmacokinetic PK 61 pharmacokinetic characteristics 61 mg administered orally 61 log# IU mL 61 BRAF V#E mutation 61 ibandronate 61 colorectal adenoma 61 prospectively randomized 61 Cmax 61 ASCUS 61 calculated creatinine clearance 61 abnormal p# biomarker 61 mcg Albuferon 61 serum phosphorus 61 Kaplan Meier method 61 antithymocyte globulin 61 calcineurin inhibitor 61 hepatitis C genotype 61 ATACAND 61 retinal vein occlusion 61 revascularizations 61 uncorrected visual acuity 61 lopinavir 61 IRLS score 61 secondary efficacy endpoint 61 colorectal carcinomas 61 Capesaris 61 mg Proellex 61 grade cervical intraepithelial 61 p = #.# [003] 61 ug mL 61 neutrophil counts 61 lipid lowering agents 61 surgically resected 61 splenectomized patients 61 randomized controlled trials RCTs 61 liposomal amphotericin B 61 SLN biopsy 61 3mg/kg 61 recurrent metastatic 61 lamivudine monotherapy 61 elevated creatinine 61 ARCALYST ® 61 carcinoembryonic antigen 61 hypogonadal 61 NYHA functional class 61 relapsed ALL 61 hemoglobin concentrations 61 oral antidiabetic medication 61 dose escalation phase 61 serum phosphorous 61 nonmetastatic prostate cancer 61 NNT = 61 BEXXAR Therapeutic Regimen 61 decitabine 61 dacarbazine 61 antiangiogenic therapy 61 INC# 61 serum thyroglobulin 61 highest tertile 61 anemia hemoglobin 61 latent celiac disease 61 beta estradiol 61 CYPHER Stent 61 statin monotherapy 61 serum phosphate levels 61 rapid virological response 61 serum clusterin levels 61 alanine aminotransferase 61 Severity Index PASI 61 NPH insulin 61 mg/m2/day 61 #F FDG 61 p# antigen 61 isoprostane 61 underwent radical prostatectomy 61 treatment naive genotype 61 Amrubicin 61 sitaxsentan 61 Score DAS# 61 busulfan 61 BRIM3 61 BPH Symptom Score 61 low dose cytarabine 61 neutropaenia 61 Ophena TM 61 KRAS wild 61 estramustine 61 PCa 61 PROSTVAC VF 61 phase IIIb 61 INCB# [003] 61 dose dexamethasone 61 adenotonsillectomy 61 PNH patients 61 creatinine ratio 61 TIMP 1 61 leukocyte count 61 TKAs 61 Events MACE 61 symptomatic VTE 61 Baseline characteristics 61 CIN3 + 61 postprocedure 61 mcg kg REBETOL 61 hemagglutination inhibition 61 allogeneic HSCT 61 verteporfin 61 allogeneic stem cell 61 rt PA 61 RE LY ® 61 MGUS 61 albumin excretion rate 61 colesevelam HCl 61 biologic DMARD 61 axillary node 61 Postoperative complications 61 seropositive 61 MACCE 61 null responders 61 Rate ORR 61 pegaptanib 61 prostate cancer CaP 61 DOXIL 61 distant metastases 61 postoperative complication 61 perioperatively 61 neurologic progression 61 breast carcinomas 61 laboratory abnormalities 61 microbiological eradication 61 LVEF 61 budesonide foam 60 HES CEL 60 divalproex sodium 60 mg simvastatin 60 zotarolimus eluting stent 60 coronary stenosis 60 COPERNICUS 60 intracranial hemorrhage ICH 60 K ras mutations 60 EDEMA3 60 μg ml 60 Rating Scale MADRS 60 RARP 60 pain palliation 60 trials RCTs 60 Phase #/#a 60 QIDS SR 60 Pemetrexed 60 autologous chondrocyte implantation 60 progression TTP 60 unresectable stage 60 fallopian tube cancers 60 Median survival 60 glycosylated hemoglobin HbA1c 60 AST ALT 60 generalized edema 60 spontaneous bowel movements 60 hypophosphatemia 60 pelvic lymphadenectomy 60 Natalizumab 60 mg eq 60 adjuvant hormonal therapy 60 radial artery grafts 60 dimeglumine 60 prostatic adenocarcinoma 60 AGHD 60 pancreatic adenocarcinoma 60 Follicular Lymphoma 60 sorafenib Nexavar 60 CDAI score 60 saline placebo 60 neutropenic sepsis 60 cancer mCRC 60 indinavir 60 darunavir ritonavir 60 dose Iluvien 60 parasitemia 60 metastatic HRPC 60 tumor resection 60 confidence intervals CIs 60 ALT elevation 60 crizotinib PF # 60 pharmacokinetic PK study 60 Recurrence Score 60 daunorubicin 60 phase IIb study 60 radezolid 60 mitoxantrone chemotherapy 60 RESIST studies 60 clinicopathological 60 Aptivus ® 60 immunohistochemical analysis 60 peginterferon alfa 2b 60 ara C 60 intravenous dosing 60 ezetimibe simvastatin 60 liver metastasis 60 Cystatin C 60 hepatic resection 60 transaminases 60 ug ml 60 inhibitor RG# 60 transaminase levels 60 Non inferiority 60 antiandrogens 60 clinico pathological 60 locoregional disease 60 sipuleucel T 60 urine cytology 60 Thrombolysis 60 nonadherent 60 NRTI backbone 60 Patency 60 glycosylated hemoglobin levels 60 metastatic renal cell carcinoma 60 mIU ml 60 glycated hemoglobin HbA1c 60 tenecteplase 60 viral kinetic 60 tirofiban 60 troponin T 60 Ozarelix 60 follicular lymphoma FL 60 REYATAZ ritonavir 60 HCV Genotype 60 moderate renal impairment 60 bortezomib refractory 60 cGy 60 resected 60 pimecrolimus 60 Platelet counts 60 oral Hycamtin 60 oral prednisolone 60 Telbivudine 60 interferon ribavirin 60 serum antibody 60 preoperatively 60 azilsartan medoxomil 60 radical cystectomy 60 FOSRENOL ® 60 haematological 60 ZACTIMA 60 IV bisphosphonates 60 virologic 60 titers 60 pegylated interferon alfa 2b 60 duplex ultrasonography 60 PROCHYMAL 60 CSBM 60 fasting plasma 60 lenalidomide dexamethasone 60 metastatic GIST 60 #mg/m# [002] 60 riociguat 60 events SAEs 60 elacytarabine 60 clinically localized prostate 60 TRAIL R1 60 androgen suppression 60 PegIFN 60 pimecrolimus cream 60 Cervista HPV HR